Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives $137.15 Consensus PT from Brokerages

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have been assigned an average rating of “Moderate Buy” from the fifteen ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, thirteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $137.1538.

Several analysts have issued reports on the company. Wall Street Zen cut Abivax from a “hold” rating to a “sell” rating in a research report on Sunday, April 26th. Jefferies Financial Group assumed coverage on Abivax in a research report on Monday, March 16th. They set a “buy” rating and a $160.00 target price on the stock. Morgan Stanley increased their target price on Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a research report on Friday, January 9th. Oddo Bhf reaffirmed an “outperform” rating on shares of Abivax in a research report on Thursday, April 9th. Finally, Wedbush assumed coverage on Abivax in a research report on Tuesday, February 24th. They set an “outperform” rating and a $110.00 target price on the stock.

Abivax Stock Up 10.5%

Shares of NASDAQ:ABVX opened at $117.38 on Friday. Abivax has a 52-week low of $5.59 and a 52-week high of $148.83. The stock has a market cap of $9.31 billion, a P/E ratio of -21.86 and a beta of 1.68. The business’s 50 day moving average is $117.02 and its 200 day moving average is $116.30.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Saturday, February 14th. The company reported ($1.20) earnings per share (EPS) for the quarter. The company had revenue of $0.52 million during the quarter. On average, sell-side analysts anticipate that Abivax will post -3.84 EPS for the current fiscal year.

Institutional Trading of Abivax

Several hedge funds and other institutional investors have recently bought and sold shares of ABVX. UBS Group AG boosted its position in Abivax by 2,561.0% during the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock valued at $378,761,000 after acquiring an additional 4,293,606 shares in the last quarter. Darwin Global Management Ltd. bought a new stake in Abivax during the 3rd quarter valued at $263,698,000. Morgan Stanley boosted its position in Abivax by 114.3% during the 4th quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock valued at $425,062,000 after acquiring an additional 1,681,277 shares in the last quarter. Paradigm Biocapital Advisors LP bought a new stake in Abivax during the 3rd quarter valued at $132,800,000. Finally, TCG Crossover Management LLC boosted its position in shares of Abivax by 17.4% in the 3rd quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after purchasing an additional 1,055,000 shares in the last quarter. Institutional investors own 47.91% of the company’s stock.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.